Karin Schmitt

Karin Schmitt has a long history of work experience in the field of biotechnology. Karin began their career in 1998 as a Director at Exelixis, where they managed a genomics group of 40+ scientists and led comprehensive technology assessment and due diligence efforts. In 2004, they moved to Open Biosystems (which was later acquired by Thermo Fisher) as their Senior Director, where they successfully launched an induced pluripotent stem cell product and developed deal prospects for multiple companies to term sheet status. In 2010, they became the Technology Manager at Cambridge Enterprise, followed by a role as R&D Director at Horizon Discovery in 2012. In 2017, they joined PredictImmune as their Vice President of Research Operations, and in 2019 they became the Chief Business Officer at Mogrify. In 2022, they assumed roles as Senior Advisor at Namier Capital Partners and Non Executive Director at StemBond Technologies, as well as Chief Operating Officer at Mursla.

Karin Schmitt has a Postdoc from the University of Cambridge in the Department of Genetics and a Ph.D. from the University of Southern California in Molecular Biology.